Bavencio misses in Phase III for NSCLC

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) said Bavencio avelumab missed the primary endpoint in the Phase III JAVELIN Lung 200 trial to treat locally advanced, unresectable, recurrent

Read the full 280 word article

User Sign In